Keown: Daniel James will be regretting Man Utd moveby Paul Vegas18 days agoSend to a friendShare the loveArsenal title winner Martin Keown says Daniel James will be regretting his move to Manchester United.Keown reckons the Wales international is United’s youngest but best player. Heaping praise on James, Keown said on Match of the Day: “Daniel James must be thinking ‘who have I signed for here?’ “He’s their youngest player, but he’s their best player.”Manchester United were beaten 1-0 by Newcastle on Sunday. About the authorPaul VegasShare the loveHave your say
Saturday is #AveryStrong day for the Nebraska men’s basketball program. Avery Harriman, the 7-year-old son of Huskers’ assistant coach Chris Harriman, has battled leukemia since he was 2. He’s been an inspiration to Tim Miles’ team this season and the Huskers’ players are constantly interacting with their No. 1 fan. Saturday’s event will be part of the National Association of Basketball Coaches Suits and Sneakers Awareness Week. Chris Harriman says #Huskers players are constantly asking about Avery. “Its fun to see them be happy when hes doing well” #AveryStrong— Jake Bockoven (@jakebockoven) January 23, 2015Nebraska (11-7, 3-3 Big Ten) is set to host Michigan State (13-6, 4-2 Big Ten) in Lincoln Saturday. During the game, the Huskers’ students will be wearing #AveryStrong T-shirts. First 1,500 students. #GBR “@HuskerSports: Getting the shirts in place for #AveryStrong tomorrow. #Huskers” pic.twitter.com/SpUsRoHGml— Nebraska Huskers (@Huskers) January 23, 2015Nebraska and Michigan State are set to tip off at 4 p.m. E.T. The game will be televised on ESPN.
Mississippi State Hype VideoMississippi State suffered a tough loss to Georgia Tech in last year’s Orange Bowl, but all in all, the Bulldogs had a great season. MSU opened the 2014 campaign with nine straight victories, including wins over LSU, Auburn and Arkansas, before falling in a close contest to Alabama. The Bulldogs, in early November, were the No. 1 ranked team in the country. And they posted double-digit victories for just the second time in their program’s history.The 2015 Bulldogs aren’t being picked by many to be quite as successful, but with star quarterback Dak Prescott returning, they may surprise a few people. Thursday, the school released an awesome hype video titled “Relentless” to tease the 2015 campaign. Enjoy, MSU fans:
Spanish telco Telefónica has unveiled its Spanish football programming line-up but has yet to strike a deal with Catalan broadcaster Mediapro to carry its BeIN Sports channel, giving it access to European Champions League and Europa League matches as well as coverage of European and international leagues.The Liga Adelante offering on Telefónica’s Movistar+ service will include coverage of La Liga matches in HD, with 11 fixtures daily to be aired on the Canal+ Liga.Telefónica is also introducing eight-camera coverage of matches, with two mini-cameras providing coverage of the changing rooms of the teams for the final three minutes before they go out onto the field.The telco will also provide multiscreen coverage via Yomvi and the Movistar+ Fútbol App.Telefónica has yet to strike a deal with Mediapro to include BeIN Sports as part of its offering, despite the latter being available via the services of rival telcos Vodafone and Orange and Asturias region cable operator Telecable.According to sports news website Palco23, citing unnamed sources familiar with the negotiations, talks are stalled over the question of Mediapro’s demand for minimum guaranteed payments.
Source:https://www.tum.de/nc/en/about-tum/news/press-releases/detail/article/35173/ Reviewed by James Ives, M.Psych. (Editor)Jan 16 2019If a pregnant woman gains excessive weight, it can pose a problem for both the mother and child. As a solution, regular counseling appointments have been proposed. Based on results with 2286 women, a team of the Technical University of Munich (TUM) in cooperation with the Competence Center for Nutrition (KErn) has now shown that although counseling appointments as part of routine prenatal care can encourage a healthier lifestyle, it does not reduce weight gain.If a woman gains excessive weight during pregnancy, it could lead to gestational diabetes, an increased risk of cesarean section or excessive birth weight of the newborn. The goal of the Bavarian Healthy Living in Pregnancy Study (GeliS) was to make pregnant women aware of the problem and to improve their dietary behavior and physical activity. More than 70 medical and midwife practices in Bavaria participated in the study.Women in the study group received three counseling sessions (30?45 minutes each) from week 12 of pregnancy, followed by another consultation several weeks after childbirth as part of their preventive check-ups. They also received additional information material as well as forms that allowed them to independently record and monitor their weight gain and physical activity. The control group only received the information material.Slight reduction in newborn weightStudy Director Professor Hans Hauner, Professor of Nutritional Medicine at the TUM, explains the initial findings: “Unfortunately, the counseling concept proved unsuccessful and had no measurable effect on maternal weight gain.” Despite the counseling, over 45 percent of the participants gained more weight than recommended by the international standard of the Institute of Medicine (IOM) ? over 14 kilograms on average. Nor did the counseling lead to a reduction in complications such as gestational diabetes, hypertension or premature labor.Related StoriesPre-pregnancy maternal obesity may affect growth of breastfeeding infantsOpioids are major cause of pregnancy-related deaths in UtahNew research examines whether effects of alcohol/pregnancy policies vary by raceNevertheless, his research team did find some positive effects: An initial look at the extended data shows that many pregnant women did in fact pay close attention to their diet and exercised regularly. In addition, more than 85 percent of women continued the program to the end and readily took the advice they received to heart. “Evidently, that was not enough to reduce their weight gain. What we saw, however, was a reduction in the size and weight of the babies of the women who participated in the program. That, too, is a small but important achievement,” Hauner says. The study team also recommends that counseling sessions be started before the 12th week of pregnancy.Main criterion: suitability for routine useIn addition, a special feature of the study was the fact that the counseling sessions were integrated into routine prenatal check-ups. It is the largest study in the world to use this approach. “It was important to us that the concept be suitable for routine use. The pregnant women did not have to appear for any additional appointments, and the effort on the part of the doctors and midwives was well defined. Only such solutions are practicable. “Numerous studies have looked after and monitored pregnant women with the help of separate regular appointments,” Hauner says. “Even if that has a positive effect, it’s not a practical solution for all pregnant women ? and that should be the goal,” Hauner says.
Source:https://www.mdanderson.org/newsroom/castration-resistant-prostate-cancer-responds-to-immunotherapy-combination.h00-159300678.html Reviewed by James Ives, M.Psych. (Editor)Feb 15 2019Two checkpoint inhibitors provide early encouraging results for immunologically cold diseaseSome patients with metastatic prostate cancer respond to a combination of immune checkpoint inhibitors after hormonal therapy and chemotherapy have failed, according to early results from a clinical trial led by investigators at The University of Texas MD Anderson Cancer Center presented today at the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco.Principal investigator Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology and Immunology at MD Anderson, said the results of combining the CTLA-4 blocking drug ipilimumab with the PD-1 inhibitor nivolumab provide an encouraging step for a cancer that’s been highly resistant to immune checkpoint therapies.Research by Sharma and 2018 Nobel Laureate Jim Allison, Ph.D., chair of Immunology, leaders of MD Anderson’s immunotherapy platform, provided a rationale for combining the two drugs. The platform is part of MD Anderson’s Moon Shots Program™, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients’ lives.Among castration-resistant patients who had progressed after second-generation hormonal therapy (cohort 1), 25 percent (8 of 32) had their tumors shrink from the immunotherapy combination at a median follow-up of 11.9 months. Among those who progressed after chemotherapy and hormonal therapy (cohort 2) 10 percent (3 of 30) had a response at median follow-up of 13.5 months.”This was the first combination trial of two immune checkpoint therapies in prostate cancer,” Sharma said. “These results support the idea that immune checkpoint blockade can play an important role in the treatment of these patients and provide the foundation to test this strategy in a larger clinical trial.”There were four complete responders, two in each cohort, among the 62 patients who could be evaluated for tumor growth.Side effects from the combination were consistent with those experienced in previous combination trials for other cancers, with 42 percent of patients in cohort 1 and 53 percent in cohort 2 experiencing grade 3 to 5 adverse events. Among cohort 1, 33 percent had to discontinue participation due to adverse events, with 35.6 percent having to withdraw from cohort 2. The most common adverse events were diarrhea, fatigue, skin rash, nausea and hypothyroidism. Four patients died from treatment-related adverse events, two in each cohort.Related StoriesResearchers identify potential drug target for multiple cancer typesLiving with advanced breast cancerStudy reveals link between inflammatory diet and colorectal cancer riskDisease progression was the most common reason to leave the trial, with 51.1 percent of cohort 1 and 44.4 percent of cohort 2 discontinuing for that reason.The researchers also analyzed a number of biomarkers and found that higher tumor mutational burden was associated with response.Combination heats up cold tumorIn previous clinical trials, neither drug succeeded as single therapy against prostate cancer, a so-called “cold” malignancy because it does not attract the attention of the immune system. Few T cells, the adaptive immune system’s targeted warriors, infiltrate prostate tumors.In a phase I trial, no patients responded to nivolumab alone because the PD-1 inhibitor requires an immune response to be under way in order to attack tumors.The multi-center combination clinical trial by Bristol-Myers Squibb, maker of both drugs, was organized after research published in Nature Medicine by Sharma and Allison, provided scientific underpinning for the combination in prostate cancer.Analyzing tumor samples before and after treatment in a clinical trial of ipilimumab and the anti-hormonal drug Lupron, Sharma, Allison and colleagues found that ipilimumab caused an immune response to the cancer reflected by major T cell penetration of tumors.They also found that PD-L1, a ligand that turns on the PD-1 checkpoint on T cells, was heavily expressed by the tumor and surrounding tissue in response, shutting down the T cell attack. Sharma and Allison hypothesized that combination treatment would induce an immune response with ipilimumab and then protect that response from deactivation by PD-1 with nivolumab.Sharma said investigators and sponsor Bristol-Myers Squibb are designing a follow-up trial that includes altering either the dosing or scheduling of ipilimumab with the goal of reducing side effects.Patients in the current trial, CheckMate-650, will be assessed for overall response rate and radiographic progression-free survival as primary endpoints and overall survival as a secondary endpoint.Allison has received royalties from Bristol-Myers in the past in connection with the development of ipilimumab but no longer receives such payments.
Reviewed by James Ives, M.Psych. (Editor)Mar 18 2019The arthroscopic superior capsule reconstruction (SCR) surgical technique offers patients with irreparable rotator cuff tears restored shoulder function and the opportunity to return to sports and physically-demanding work, according to research presented today at the AOSSM/AANA Specialty Day in Las Vegas, Nevada. The study, which examined patient outcomes up to five years after surgery, built upon earlier research which examined short-term patient results.”We studied 30 patients who were treated with arthroscopic SCR, and consistently saw improvements in outcomes related to shoulder function and the daily lives of those treated,” noted lead researcher Teruhisa Mihata, MD, PhD, from Osaka Medical College in Osaka, Japan. “The technique allowed 11 of 12 patients who had previously worked to return full-time at five-year follow-up, and all eight who had participated in sports to return to play.”Related StoriesAMSBIO offers new, best-in-class CAR-T cell range for research and immunotherapyPenn Medicine and Grand View Health partner to provide advanced orthopedic careTen-fold rise in tongue-tie surgery for newborns ‘without any real strong data’The study measured both American Shoulder and Elbow Surgeons (ASES) and Japanese Orthopaedic Association (JOA) scores in patients, which improved significantly at both one and five years after surgery. The average ASES scores rose from 29.0 before surgery to 83.0 at one year and 92.3 at five years after surgery, with JOA scores rising from 51.5 before surgery to 85.9 and 91.4, respectively. Active elevation increased from 85 degrees prior to surgery to 151 degrees 5 years after the operation. Out of 30 patients followed for five years, only three (10%) experienced graft tears. Those who demonstrated graft healing also showed no sign of glenohumeral osteoarthritis during the five-year period.”Our latest research shows continued promise for the arthroscopic SCR technique, particularly to restore a patient’s shoulder function and allow them to return to work or sports if they so choose,” said Mihata. “We plan to continue studying longer-term outcomes for patients, focusing on continued function and the appearance of osteoarthritis.” Source:https://www.sportsmed.org/aossmimis/Members/About/Press_Releases/2019-Specialty-Day/Treating-Irreparable-Rotator-Cuffs-Injuries.aspx
Source:https://home.liebertpub.com/news/is-adenosine-the-missing-link-in-restless-leg-syndrome/3534 Reviewed by James Ives, M.Psych. (Editor)Apr 4 2019Researchers have identified a common mechanism implicating adenosine in the cause of restless leg syndrome (RLS) symptoms — the periodic limb movements characteristic of RLS and the state of enhanced arousal that both disrupt sleep. Preclinical findings in a rat model of RLS and clinical results in humans together suggest that targeting the pathogenetic downregulation of adenosine A1 receptor (A1R) may be a promising therapeutic strategy, according to an editorial published in Journal of Caffeine and Adenosine Research, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Click here to read the full-text article free on the Journal of Caffeine and Adenosine Research website until May 3, 2019.Related StoriesAn active brain and body associated with reduced risk of dementiaNeural pathways explain the relationship between imagination and willingness to helpStudy offers clues about how to prevent brain inflammation in Alzheimer’sRLS is a common disorder, with about 5% of individuals in the U.S. and Europe reporting symptoms, as described in the article “The Adenosine Hypothesis of Restless Legs Syndrome”. More than one pathogenetic mechanism likely underlies the spinal cord-related and non-spinal cord-related aspects of the disorder, and researchers have long looked for a biochemical link that could serve as a new therapeutic target. A combination of preclinical and clinical findings has shown that brain iron deficiency (BID) is an early factor in the pathophysiology of RLS and that BID in rodents causes downregulation of A1Rs in the brain.”Based on these results,” Editor-in-Chief of Journal of Caffeine and Adenosine Research, Sergi Ferré, MD, PhD, and his research colleagues in the Integrative Neurobiology Section, National Institute on Drug Abuse, National Institutes of Health (Baltimore, MD), “have hypothesized that a hypoadenosinergic state secondary to A1R downregulation could be mostly responsible for the hyperglutamatergic and hyperdopaminergic states of RLS that determine the sensorimotor symptoms of RLS as well as the hyperarousal component.” They add, “We, therefore, predicted that inhibitors of equilibrative nucleoside transporters, by increasing the striatal extra-cellular levels of adenosine, could provide a new therapeutic approach for RLS.”
Canada and Quebec province, as well as tech giant Apple, announced Thursday their backing of aluminum producers Alcoa and Rio Tinto’s new joint venture to develop a carbon-free smelting process. Citation: Canada, Apple back development of carbon-free aluminum smelting tech (2018, May 10) retrieved 18 July 2019 from https://phys.org/news/2018-05-canada-apple-carbon-free-aluminum-smelting.html © 2018 AFP Aluminum is used in everything from cars and planes, softdrink cans, foil and window frames, as well as in Apple smartphones, tablets and computers Toyota invests Can$1.4 billion in Canada plants This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only. Prime Minister Justin Trudeau made the announcement with executives of the three companies on hand.Apple is investing Can$13 million (US$10 million) in the joint venture, and will provide technical support.Rio and Alcoa are investing Can$55 million (US$43 million), while the Canadian and Quebec governments will each invest Can$60 million (US$47 million) in a first round of financing.The technology promises to be “the most significant innovation in the aluminum industry in more than a century, and marks a decisive step forward in the fight against climate change,” said a statement.”Once fully developed and implemented, the ground-breaking technology will virtually eliminate the Canadian aluminum industry’s carbon footprint.”Aluminum is used in everything from cars and planes, softdrink cans, foil and window frames, as well as in Apple smartphones, tablets and computers.The sector employs 10,500 people in Canada.Alcoa is the largest aluminum producer in the United States and Rio is the world’s second-largest miner.Their joint venture is to be named Elysis and headed by Rio executive Vincent Christ. It will be based in Montreal, with a research facility in Quebec’s Saguenay region.The new technology is expected to be ready for licensing to retrofit smelters or build new facilities by 2024.According to Ottawa, it has the potential to reduce annual greenhouse gas emissions by approximately 6.5 million metric tonnes in Canada—the equivalent of taking 1.8 million cars off the road.”We are proud to be part of this ambitious new project, and look forward to one day being able to use aluminum produced without direct greenhouse gas emissions in the manufacturing of our products,” Apple chief executive Tim Cook said in the statement. Explore further